Abdul Memon, MD
Interventional Cardiology · Globe, AZNPI 1093781346
Payments from drug & device makers
Across 157 payments — averaging $82.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Siemens Medical Solutions USA, Inc.$10K
- Abbott$522
- Boston Scientific$337
- Shockwave Medical, Inc$188
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$188
- Novartis$186
- plus $2K from 32 others
What the payments were for
- Speaking & faculty fees$9,18071%
- Travel & lodging$2902%
- Food & beverage$3,48127%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Siemens Medical Solutions USA, Inc. | 3 | $9,612 |
| Abbott | 11 | $522 |
| Boston Scientific | 17 | $337 |
| Shockwave Medical, Inc | 9 | $188 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $188 |
| Novartis | 13 | $186 |
| Kestra Medical Technology Services, Inc. | 7 | $185 |
| Boehringer Ingelheim | 8 | $171 |
| Medtronic(2 entities) | 8 | $148 |
| AstraZeneca | 8 | $144 |
| Merck | 5 | $123 |
| E.r. Squibb & Sons, L.L.C. | 5 | $102 |
| Abiomed | 6 | $89 |
| Bardy Diagnostics, Inc. | 5 | $85 |
| Amgen | 4 | $78 |
| Heartflow, Inc. | 2 | $70 |
| Tactile Systems Technology Inc | 2 | $69 |
| Johnson & Johnson | 4 | $68 |
| ZOLL Respicardia, Inc. | 3 | $62 |
| Cagent Vascular Inc | 2 | $61 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $60 |
| Baxter Healthcare | 2 | $48 |
| Pfizer | 3 | $44 |
| Biotronik Inc. | 3 | $41 |
| Bayer | 2 | $40 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Novo Nordisk | 1 | $24 |
| Gilead | 2 | $24 |
| Watermark Medical, Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $20 |
| Vivaquant Inc, Dba Rhythm Express | 1 | $19 |
| Impulse Dynamics (USA) Inc. | 1 | $18 |
| Scpharmaceuticals Inc. | 1 | $17 |
| Infobionic, Inc | 1 | $16 |
| Elutia, Inc. | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
| Inspire Medical Systems, Inc. | 1 | $14 |
| Cardinal Health 200 LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,965 in reported general payments places this provider in the 50th percentile of 223 interventional cardiology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 227 | $231,659 |
| XareltoRivaroxaban | 206 | $211,357 |
| EliquisApixaban | 229 | $210,942 |
| JardianceEmpagliflozin | 96 | $91,310 |
| FarxigaDapagliflozin Propanediol | 19 | $25,824 |
| BrilintaTicagrelor | 30 | $25,505 |
| Repatha SyringeEvolocumab | 35 | $18,447 |
| VascepaIcosapent Ethyl | 22 | $11,962 |
| Rosuvastatin Calcium | 498 | $7,528 |
| Metoprolol Succinate | 558 | $7,081 |
| ClopidogrelClopidogrel Bisulfate | 474 | $5,667 |
| Losartan Potassium | 325 | $3,223 |
| Atorvastatin Calcium | 372 | $3,135 |
| Diltiazem 12hr ErDiltiazem Hcl | 14 | $2,804 |
| Carvedilol | 350 | $2,787 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $186 | $231,659227 claims |
| Johnson & JohnsonXarelto | $68 | $211,357206 claims |
| PfizerEliquis | $44 | $210,942229 claims |
| Boehringer IngelheimJardiance | $171 | $91,31096 claims |
| AstraZenecaFarxiga, Brilinta | $144 | $51,32949 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 223 interventional cardiology providers in Arizona.
Other interventional cardiology in Globe
- Paul SorajjaPhoenix$8.8M
- Thomas WaggonerTucson$4.1M
- Hursh NaikAvondale$2.2M
- Nabil DibGilbert$2.2M
- Timothy ByrnePhoenix$2.1M
- Ashish PershadChandler$1.4M
- Mohamad LazkaniPhoenix$1.1M
- Parminder SinghPhoenix$854K
- Samuel ButmanCottonwood$706K
- Ajay TuliTucson$705K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.